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ABSTRACT
Objective: To estimate the differential impact of obesity on
prevalence and medical costs overall and for three major
obesity-related complications (diabetes, dyslipidemia, and
their joint occurrence) over the life cycle.
Methods: The impact of obesity on age-speciﬁc medical
costs and diagnosed prevalence was estimated using econo-
metric analyses of the 2001–03 Medical Expenditure Panel
Survey data. Obesity was measured using body mass index.
Results: Obesity increases the risks for diabetes and dyslip-
idemia at all ages. Obesity also increases per person medical
costs and the magnitude of the increase is greater at older
ages. Although obese individuals represent 49% of the pop-
ulation with diabetes, they are responsible for 56% of total
diabetes costs. They also represent 34% of the population
with dyslipidemia yet are responsible for 52% of total dysl-
ipidemia costs.
Conclusions: These results highlight the potential savings
over the life cycle resulting from effective interventions that
target obesity and/or its comorbid disorders. Targeting indi-
viduals with both obesity and comorbidities is particularly
important given the high medical costs associated with this
subset of the obese population. Effective strategies that
improve the comorbidity proﬁle of these individuals may
have the best chance of showing a positive ﬁnancial return.
Keywords: costs, diabetes, dyslipidemia, life cycle, metabolic
syndrome, obesity.
Introduction
Over the past several decades there has been a rapid
rise in the prevalence of obesity. Currently, 31% of US
adults are obese, an increase from 15% in 1976–80
and 23% in 1988–94 [1]. These increases in obesity
rates have spurred corresponding growth in the prev-
alence of several diseases, including type II diabetes,
cardiovascular disease, hypertension, osteoarthritis,
several types of cancer, gallbladder disease, and sleep
apnea [2].
Partly as a result of the increase in obesity rates,
aggregate health spending has also ballooned. The
average obese adult increases annual medical expendi-
tures by roughly $732 (or 37%) per year; complica-
tions from obesity now cost the US medical system
over $93 billion annually [3]. Nevertheless, focusing
on average or aggregate prevalence and cost increases
ignores the temporal impact of obesity over the life
cycle. As a result of the chronic nature of obesity-
related diseases, it is likely that the impact of obesity
on both prevalence and annual medical costs varies
over the life cycle. For example, Must et al. [4] show
that prevalence ratios for select obesity-related diseases
are lower among those greater than age 55 years com-
pared to adults less than age 55 years. Contrarily, Fin-
kelstein et al. [3] show that the increase in per person
obesity-attributable medical spending is roughly twice
as great for Medicare recipients than for the general
population.
The goal of this analysis is to further explore the
impact of obesity over the life cycle. First, using
nationally representative data, we quantify the age-
speciﬁc prevalence of: 1) diabetes; 2) dyslipidemia; and
3) these two conditions combined among obese and
nonobese individuals and compare prevalence ratios
over the life cycle for these two groups. We hypothe-
size that the prevalence of these conditions is likely to
be similar among young individuals, regardless of
body mass index (BMI, deﬁned as weight in kg/height
in m2), but will be signiﬁcantly greater among obese
individuals at older ages. Focusing on these conditions
is important as they comprise two of the ﬁve risk fac-
tors used to deﬁne the metabolic syndrome [5] accord-
ing to National Cholesterol Education Program Adult
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Treatment Panel III (NCEP-ATP III) guidelines. The
metabolic syndrome, in turn, greatly increases the risk
of coronary heart disease and other diseases [6]. The
remaining risk factors, including high waist circumfer-
ence and elevated blood pressure and triglycerides
were not available in the data used for this analysis so
we were unable to measure metabolic syndrome using
all of the NCEP-ATP III guidelines.
Using the same data, we then explore the impact of
obesity on age-speciﬁc per person medical costs in the
general population, and among individuals with each
of these three conditions. We then combine the prev-
alence and per person cost data to estimate aggregate
medical costs for diabetes and dyslipidemia at select
age intervals, and the percent of aggregate costs that
accrue to those who are obese. Again, we hypothesize
that as a result of the chronic nature of obesity-related
diseases, the impact of obesity on annual medical costs
will be small among young obese adults and will
increase with increasing age. We further suggest that
the impact of obesity on annual medical costs will be
greater among those with precursors to the metabolic
syndrome, as excess weight may simultaneously exac-
erbate these conditions and complicate treatment. We
conclude with a discussion of the implications of these
results for obesity prevention and treatment.
Methods
Data
We used the 2001–03 Medical Expenditure Panel Sur-
vey (MEPS) data for all analyses. MEPS is a nationally
representative survey of the US civilian, noninstitution-
alized population administered by the Agency for
Healthcare Research and Quality. MEPS includes data
on demographics, self-reported medical conditions,
and detailed medical expenditure data reported by
households. The household data are augmented with
data from medical providers and insurers and profes-
sional coders convert verbatim self-reported narratives
into fully speciﬁed International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation (ICD-9-
CM) codes. MEPS follows each respondent over
2 years using an overlapping panel design. To obtain
sufﬁcient sample size for the disease subgroups, we
pooled 3 years of data. We excluded pregnant women
and those with missing data. Our ﬁnal analysis sample
includes 66,300 adults. Survey weighting variables
were used throughout all analyses to generate nation-
ally representative estimates for the civilian, noninsti-
tutionalized population.
Obesity status was based on self-reported height and
weight, which were converted into BMI in the MEPS
data set. The analysis focused on BMI because other
measurements of obesity, such as waist circumference
for measurement of abdominal obesity, were not avail-
able. Normal weight included a BMI greater than or
equal to 18.5 and less than 25, underweight included a
BMI less than 18.5, overweight included a BMI greater
than or equal to 25 and less than 30, and obese included
a BMI greater than or equal to 30. To preserve respond-
ent conﬁdentiality, MEPS recodes almost all fully
speciﬁed ICD-9-CM codes into 3-digit ICD-9 code
categories. MEPS also group related fully speciﬁed ICD-
9-CM codes into clinical classiﬁcation categories. We
used the clinical classiﬁcation categories for diabetes
with and without complications (codes 49 and 50, or
ICD-9-CM 250.xx, 790.2, 790.21, 790.22, 790.29,
791.5, 791.6, V45.85, V53.91, V65.46) and “disorders
of lipid metabolism” (code 53, or ICD-9-CM 272.0,
272.1, 272.2, 272.3, 272.4) to identify individuals with
diabetes and/or dyslipidemia, respectively.
Adjusted Prevalence Model
The age-speciﬁc prevalence of diagnosed diabetes, dys-
lipidemia, and their joint occurrence in the MEPS data
was calculated using a logistic regression to control for
factors that may inﬂuence differences in the prevalence
of obesity. These adjustments help to isolate the age-
speciﬁc impact of obesity on the conditions of interest
and minimize confounding by sociodemographic fac-
tors. We included covariates for age, age-squared, age-
cubed, sex, race/ethnicity (white, African American,
Hispanic), region (north-east, midwest, south, west),
rural residence, income (below the federal poverty
level (FPL), 100% to 199% of FPL, 200% to 399% of
FPL, and 400% or greater than FPL), level of educa-
tion (less than college degree, bachelor’s degree, post-
graduate degree, other degree), marital status (single,
married, divorced, widowed), and insurance status
(covered or not covered). Predicted prevalence rates by
age were then generated for a representative cohort
using the regression coefﬁcients and the mean values
for all independent variables other than age.
Prevalence ratios for ages 20, 30, 40, 50, 60, and
70 years were computed by dividing the predicted pro-
portion obese with each of the three conditions by the
predicted proportion nonobese with each of the three
conditions. Bootstrapped 95% conﬁdence intervals
around the prevalence ratios were estimated using
1000 simulations.
Cost Model
We estimated age-speciﬁc total annual medical costs
for persons with obesity and three sets of obesity-
related complications (diabetes, dyslipidemia, and
their joint occurrence) using regression-based econo-
metric techniques. Because medical cost data are
highly skewed [7], simple linear regressions often ﬁt
the data poorly and naïve application of parametric
models, such as the common two-part ordinary least
squares model, may be affected by a variety of mis-
speciﬁcation problems [8]. We followed the procedures
in [7] and [9] to test the distribution of the cost data
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and select the most appropriate model. A two-part
generalized linear regression model with a gamma dis-
tribution and a log link was found to be most appro-
priate for the cost analysis.
Each regression was run on the age 18 to 85 years
population and included the same set of sociodemo-
graphic independent variables used in the adjusted
prevalence equations. All cost estimates were adjusted
to 2004 dollars using the medical component of the
consumer price index.
To compute the costs attributable to obesity, the
econometric model included binary terms for under-
weight, overweight, obesity, and an interaction term
between age and the obesity binary variable (normal
weight is the omitted reference group). This interaction
allows the impact of obesity to vary nonlinearly across
ages. After estimation, predicted costs were generated
for a representative obese and normal weight person of
each age using the regression coefﬁcients and the mean
values for the independent variables.
The cost models for diabetes, dyslipidemia, and
their joint occurrence used the same econometric spec-
iﬁcation as for the costs of obesity versus normal
weight. For each condition, a single model was used to
estimate costs for each condition among obese persons
and among nonobese persons, and costs for the gen-
eral population without the condition of interest. Each
model included the set of independent variables listed
earlier, plus two indicator variables, one for the con-
dition of interest interacted with obesity (BMI ≥ 30)
and another for the condition interacted with non-
obesity (BMI < 30) and corresponding interactions
between each of these variables and age. The age inter-
action terms allow the impact of each condition (with
and without obesity) to vary nonlinearly across ages.
After estimation, predicted costs were generated as
above.
Cost ratios for ages 20, 30, 40, 50, 60, and 70 years
were computed by dividing the predicted per person
medical costs for an obese person with each of the
three conditions by the predicted per person medical
costs for a nonobese person with each of the three
conditions. Bootstrapped 95% conﬁdence intervals
around the cost ratios were estimated using 1000
simulations.
Lastly, using the results of the regressions and the
full MEPS sample, we predicted total expenditures
attributable to diabetes and, separately, to dyslipi-
demia in 10-year age intervals. We also calculated the
percentage of these costs that accrue to obese individ-
uals. These estimates were generated by predicting
total costs for each age interval with the disease indi-
cator variables (with and without obesity) set to one
and then again with these variables set to zero. The dif-
ference between these two estimates represents the
costs attributable to the disease among obese and non-
obese individuals.
Results
Prevalence
Figure 1 depicts the prevalence estimates. The diag-
nosed prevalence of each of the three conditions (dia-
betes, dyslipidemia, and their joint occurrence) is
shown in a separate panel. A solid line indicates the
prevalence of each condition among persons who are
not obese and a dashed line indicates the prevalence of
the condition among obese individuals. Dotted lines
indicate the overall prevalence of each condition
among the population, and thus, represent the
weighted average of the other two lines.
The prevalence of all three conditions increases
with age, as expected. Nevertheless, none of the con-
ditions are prevalent at more than 5% until at least age
35 years, even among the higher risk obese popula-
tion. The prevalence of diabetes rises steadily after age
30 years for each segment of the population, although
the rate of increase is more rapid for obese individuals.
Consequently, prevalence approaches 30% among the
obese by age 65 years, whereas it is only about 12%
among the nonobese population and 16% among the
overall population. Both the higher prevalence and the
more rapid rise among the obese are consistent with
our hypothesis. Results for dyslipidemia are similar
although the prevalence of dyslipidemia is relatively
higher among the nonobese, especially at older ages.
As a result, the difference in dyslipidemia prevalence
between the obese and nonobese peaks at an eight per-
centage point difference around age 65 years.
Regardless of obesity status, the prevalence of both
diabetes and dyslipidemia is less than half that of
the prevalence of either diabetes or dyslipidemia. The
impact of obesity among the joint occurrence of these
conditions is substantial and increases with age, con-
sistent with our hypothesis. Given the higher pre-
valence and the smaller impact of obesity on
dyslipidemia, this result is likely dominated by obes-
ity’s impact on diabetes.
The ﬁrst three columns of Table 1 show prevalence
ratios for all three conditions. Among those aged 70 to
79 years, for example, the prevalence of diabetes is 2.4
times greater among the obese than among those who
are not obese. For diabetes, dyslipidemia, and their
joint occurrence, the prevalence ratios are greatest
among young adults, ranging from 4.27 for diabetes,
2.42 for dyslipidemia, and 6.94 for both conditions.
Nevertheless, the overall prevalence of these condi-
tions remains low—less than 2%—among younger
ages. Beyond age 30 years the prevalence ratios
decrease monotonically, with the largest decrease seen
for the joint occurrence of diabetes and dyslipidemia
(from 6.94 at age 20 to 2.54 at age 70). The relative
impact of obesity likely decreases at older ages because
individuals are more likely to develop diabetes, dysli-
pidemia, or both, independent of obesity, at older ages.
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Costs
Figure 2 depicts the results of the cost analysis. In the
upper left panel of the ﬁgure, we show per person costs
for obese and nonobese individuals at each age. The
incremental cost associated with obesity is small
among young adults but increases dramatically in sub-
sequent years, in part because of the increase in the
prevalence of diabetes, dyslipidemia, and other com-
plications. By age 65 years, average costs among obese
individuals are nearly $1700 greater than costs among
those of normal weight.
As with prevalence, costs for each of the three con-
ditions (diabetes, dyslipidemia, and their joint occur-
rence) are shown in a separate panel. For each
condition, a solid line indicates annual costs among
persons who are not obese (BMI < 30) and a dashed
line indicates annual costs among obese (BMI 30+)
individuals. Dotted lines indicate the overall annual
costs among individuals without the condition. At all
ages, costs for those with diabetes—whether obese or
not obese—are substantially higher than costs for per-
sons without diabetes. At younger ages, the nearly
$2500 to $3000 additional medical costs per year are
Figure 1 The impact of obesity on the age-speciﬁc prevalence of diabetes, dyslipidemia, and both conditions.
Table 1 Adjusted prevalence and cost ratios for diabetes, dyslipidemia, and both conditions, comparing obese to nonobese
Age
(years)
Prevalence ratio Cost ratio 
Diabetes Dyslipidemia
Diabetes and 
dyslipidemia Diabetes
Diabetes and 
Dyslipidemia Dyslipidemia
20–29 4.27 (3.64–5.01) 2.42 (2.01–2.89) 6.94 (4.82–10.23) 1.19 (0.90–1.67) 1.44 (1.14–1.83) 1.60 (1.09–2.33)
30–39 3.94 (3.50–4.45) 2.17 (1.89–2.47) 5.75 (4.34–7.76) 1.17 (0.93–1.52) 1.39 (1.16–1.66) 1.48 (1.10–1.99)
40–49 3.58 (3.29–3.90) 1.92 (1.75–2.10) 4.73 (3.87–5.86) 1.15 (0.98–1.40) 1.34 (1.19–1.54) 1.38 (1.12–1.71)
50–59 3.15 (2.98–3.33) 1.68 (1.58–1.77) 3.84 (3.36–4.40) 1.13 (1.00–1.29) 1.29 (1.20–1.42) 1.28 (1.12–1.49)
60–69 2.71 (2.58–2.85) 1.47 (1.41–1.53) 3.08 (2.77–3.41) 1.10 (1.01–1.20) 1.25 (1.19–1.34) 1.19 (1.07–1.34)
70–79 2.4 (2.25–2.56) 1.33 (1.26–1.40) 2.54 (2.22–2.92) 1.08 (0.98–1.18) 1.21 (1.13–1.32) 1.11 (0.95–1.30)
Prevalence and cost ratios are adjusted for age and other sociodemographic variables, as noted in the text. Bootstrapped 95% conﬁdence intervals are shown in parentheses.
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likely a result of prescription drugs, insulin, and
increased rates of routine care. Among older ages, the
gap between costs for those with and without diabetes
widens to over $4000 per year, likely as a result of dia-
betes complications that are known to increase with
age. Obesity increases the costs of diabetes care by
about $700 per year relative to non-obese persons, but
surprisingly, the impact of obesity is nearly constant
with age. Although not entirely consistent with our
hypothesis, a likely explanation may be that persons
with diabetes are simply at greater risk of costly com-
plications independent of their weight status. In other
words, the incremental impact of obesity is smaller
because many of the risks promoted by obesity are
already elevated by the presence of diabetes.
The impact of dyslipidemia on per person medical
costs is lower than that of diabetes at all ages, ranging
between $900 and $1800 per year at younger ages and
increasing slightly at older ages. Nevertheless, the
impact of obesity on costs for those with dyslipidemia
is larger in both absolute and relative terms than its
impact on costs for those with diabetes. The cost
impact of dyslipidemia alone, and of obesity on dysl-
ipidemia, increases gradually with age, and at a slightly
increasing rate.
Considering the joint impact of diabetes and dysli-
pidemia as precursors or proxies for the metabolic syn-
drome, the story is different. As expected, diabetes and
dyslipidemia increase medical costs substantially. The
impact of obesity on diabetes and dyslipidemia costs is
large—nearly $2000 at younger ages—but decreases
with age. The age-related impact of obesity is partly
attenuated among this group because even those at
younger ages are at signiﬁcantly greater risk for costly
adverse health outcomes. Although it is inconsistent
with our hypothesis, it is plausible that, as for diabetes,
living with both conditions makes one at risk for a
variety of costly medical complications that increase
over time. As a result, the marginal impact of obesity is
smaller at higher ages although the absolute difference
in costs remains over $1000 per year until around age
70 years.
Table 1 also shows cost ratios for all three condi-
tions. Unlike for prevalence, there is only a small
decrease in the ratios at higher ages. The decrease is
largest for those with diabetes and dyslipidemia (1.60–
Figure 2 The impact of obesity on age-speciﬁc medical costs overall and for diabetes, dyslipidemia, and both conditions.
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1.11) and smallest for those with diabetes (1.19–1.08).
Thus, the relative impact of obesity on per person med-
ical costs at different ages is far more constant than the
relative impact of obesity on disease prevalence. As
medical costs for all individuals increase with age, the
impact of obesity on costs nearly keeps pace with this
overall trend.
Figures 3 and 4 combine the prevalence and per
person cost estimates to show the aggregate predicted
costs of diabetes and dyslipidemia, respectively, and
the percentage of these costs that accrue to obese indi-
viduals. Summing across the age categories in Figure 3
reveals that the aggregate costs attributable to diabetes
for individuals between the ages of 20 and 80 years are
$53.4 billion, with 81% of these costs accruing among
individuals who are over age 50 years. Although obese
individuals represent 49% of the population with dia-
betes, they are responsible for 56% of the total costs.
Nevertheless, their share of costs rises until age
50 years, and then decreases for subsequent age
categories.
Age-speciﬁc results for dyslipidemia are shown in
Figure 4. The aggregate costs attributable to dyslipi-
demia are $39.7 billion, with 81% of these costs accru-
ing among individuals who are over age 50 years.
Although obese individuals represent 34% of the pop-
ulation with dyslipidemia, they are responsible for
52% of the total costs. The share of these costs that
accrue to obese individuals varies between 40% and
60%.
Discussion
Consistent with prior studies, we show that the burden
of obesity, diabetes, and dyslipidemia is large. We also
ﬁnd that the joint occurrence of these conditions is
especially costly. In addition, this analysis highlights
several important features that are not apparent from
aggregate analyses that do not show results by age. We
show that, although the prevalence of diabetes and
dyslipidemia is low among younger ages, the likeli-
hood of these conditions is substantially greater among
obese individuals. Moreover, not only does the preva-
lence of these conditions increase with age, but the rate
of increase of these conditions is more rapid among
obese individuals.
For the general adult population, the increase in
costs associated with obesity is relatively small at
younger ages but increases dramatically as individuals
reach their mid-30s and beyond, in part because of the
increase in diabetes, dyslipidemia, and other diseases
that obesity promotes. For those with diabetes and/or
dyslipidemia, obesity signiﬁcantly increases costs at
every age. As a result, obese individuals are responsible
for 56% of the $53.4 billion annual cost of diabetes
and 52% of the $39.7 billion annual cost of
dyslipidemia.
From a policy perspective, these results highlight
the potential savings that would accrue over the life
cycle from effective interventions that target obesity
and/or its comorbid disorders. Nevertheless, they also
reveal why employers and/or insurers may be reluctant
to ﬁnance the costs of such treatments. With roughly
one-third of the adult workforce currently obese, and
costs of obesity relatively small among young adults
(see the upper left panel of Fig. 2), employers may be
reluctant to provide broad coverage for obesity treat-
ments. If so, it may be to their advantage to target the
subset of obese individuals who have the most to gain
from effective treatments. Focusing on obese individ-
uals with diabetes and/or dyslipidemia may be an
effective strategy. This strategy offers two primary
beneﬁts. First, by limiting the pool of eligible recipi-
ents, this will reduce the total outlays required to fund
the treatment. Second, as Figure 2 reveals, these indi-
viduals are associated with greater costs at every age.
As a result, effective strategies that improve the comor-
Figure 3 Total age-speciﬁc attributable costs for the noninstitutionalized
population with diabetes, by obesity status.
Figure 4 Total age-speciﬁc attributable costs for the noninstitutionalized
population with dyslipidemia, by obesity status.
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bidity proﬁle of these individuals may have the best
chance of showing a positive ﬁnancial return.
This analysis has several limitations. First, the dis-
ease prevalence and BMI data are self-reported. We are
only able to show the impact of diagnosed (and self-
reported) conditions, and therefore miss the impact of
undiagnosed conditions; this may be important for
conditions such as diabetes or dyslipidemia, which
often go undiagnosed [10,11]. This should affect only
the prevalence estimates, as the prevalence ratios
should remain unbiased. Nevertheless, it is possible
that patients with obesity may be in greater contact
with the medical system to help control their weight,
which could lead to additional testing for risk factors
such as diabetes. The inaccuracies of self-reported
height and weight are well known in the literature,
although the impact on our results is unclear. Second,
although our analysis by age illuminates several fea-
tures not apparent in an aggregate analysis, our
approach is based on cross-sectional regressions. Thus,
we are unable to establish a ﬁrm casual and temporal
impact of obesity on these conditions versus an asso-
ciation that varies with age. Additionally, the MEPS
sample is nationally representative of the noninstitu-
tionalized population, but will miss any important fea-
tures of cost or prevalence in the institutionalized
population. All of these limitations combine to suggest
that there may be some degree of bias in the estimates.
In summary, obesity and its comorbid disorders are
responsible for an increasingly large share of aggregate
health spending. Effective interventions that reduce the
prevalence of these conditions have the potential to
improve both the health of the adult population and
the ﬁnancial health of their employers and insurers.
Source of ﬁnancial support: This project was funded by
sanoﬁ-aventis. 
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